Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as monotherapy in participants with advanced or metastatic solid tumors harboring KRAS mutations or amplification, as well as when used in combination with tislelizumab (also known as BGB-A317) in participants with nonsquamous non-small cell lung cancer (NSCLC) and used in combination with cetuximab in participants with colorectal cancer (CRC). The study consists of 2 phases: Phase 1a Dose Escalation and Safety Expansion and Phase 1b Dose Expansion.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Primary purpose
Allocation
Interventional model
Masking
177 participants in 5 patient groups
Loading...
Central trial contact
Study Director
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal